KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Long-Term Investments (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Long-Term Investments readings, the most recent being $61.2 million for Q4 2025.

  • On a quarterly basis, Long-Term Investments rose 200.96% to $61.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $61.2 million, a 200.96% increase, with the full-year FY2025 number at $61.2 million, up 200.96% from a year prior.
  • Long-Term Investments hit $61.2 million in Q4 2025 for Biocryst Pharmaceuticals, up from $39.7 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $64.3 million in Q2 2024 to a low of $3.4 million in Q1 2023.
  • Median Long-Term Investments over the past 5 years was $19.9 million (2024), compared with a mean of $25.1 million.
  • Biggest five-year swings in Long-Term Investments: soared 1766.97% in 2024 and later tumbled 84.29% in 2025.
  • Biocryst Pharmaceuticals' Long-Term Investments stood at $6.8 million in 2021, then skyrocketed by 164.71% to $18.1 million in 2022, then tumbled by 80.94% to $3.4 million in 2023, then skyrocketed by 489.93% to $20.3 million in 2024, then skyrocketed by 200.96% to $61.2 million in 2025.
  • The last three reported values for Long-Term Investments were $61.2 million (Q4 2025), $39.7 million (Q3 2025), and $10.1 million (Q2 2025) per Business Quant data.